Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The detection rate of AFP for liver cancer was 86.8%, and the exclusive diagnostic rate of AFP for hepatic FNH was 96.9%.
|
31646787 |
2020 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The concentration of alpha-fetoprotein (AFP) rises greatly in patients with liver cancer and it is a challenge to construct a sensitive AFP detection method with wide range.
|
31761168 |
2020 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Only alpha-fetoprotein levels predicted the probability of cure among Barcelona Clinic Liver Cancer-B patients.
|
31606196 |
2019 |
Malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results of clinicopathologic analysis showed that A allele at the rs737241 locus could increase the expression level of AFP (P = .007), the rs1046282 mutation C allele could increase the AFP expression level (P = .011), rs4024 locus mutation A allele could reduce the risk of vascular invasion (P = .013), rs3212948 locus mutation T allele could reduce the differentiation of liver cancer (P = .022), rs1046282 locus C allele could reduce the DNA load of hepatitis B virus (P = .035), and rs735482 A allele could increase the tumor size in HCC (P = .037).The SNPs in rs737241 for AFP gene may correlate with the occurrence of HCC.
|
30946366 |
2019 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Cox regression model revealed that liver cancer survival was independently associated with tumor size, metastasis and α-fetoprotein value.
|
31452799 |
2019 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The colorimetric immunoassay showed a linear relationship with the liver cancer marker (α-fetoprotein, AFP) in the range of 0.1-10 000 ng/mL with the detection limit of 0.46 ng/mL.
|
31074952 |
2019 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells.
|
30392891 |
2019 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
One-shot transfusion of hepatoma serum to naïve rats induced liver cancer development with gradual elevation of alpha-fetoprotein (AFP), but exosome-free hepatoma serum failed to induce AFP elevation.
|
31162867 |
2019 |
Malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using multivariate Cox regression analyses, the patient-related eGFRcre/eGFRcys ratio (hazard ratio [HR], 4.178; P = 0.007), as well as the tumor-related factors α-fetoprotein (HR, 1.000; P < 0.001) and Barcelona Clinic Liver Cancer stage (HR, 2.589; P < 0.001), were independent predictors of survival.
|
30005446 |
2019 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Liver cancer dedifferentiation markers (AFP, CD133, EPCAM, and KRT19) were found to be progressively increased while hepatocyte terminal differentiation markers (ALB, G6PC, CYP3A4, and HNF4A) were progressively decreased from HCC patients with low SOX signature scores to patients with high SOX signature scores.
|
31462277 |
2019 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In summary, the increased serum AFP levels were most evident but not specific for liver cancer patients.
|
30905450 |
2019 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
We developed a 32-gene diagnostic model that accurately distinguished early HCC (stage 0/A) based on the Barcelona Clinic Liver Cancer staging system from non-HCC (validation set: area under curve (AUC)=88.4%; (95% CI 85.8% to 91.1%)), showing superior performance over α-fetoprotein (AFP).
|
31358576 |
2019 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasma Hsp90α maintains also broad-spectrum for cancer subtypes, especially with 91.78% sensitivity and 91.96% specificity in patients with AFP-limited liver cancer.
|
31343810 |
2019 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The prognostic value of PFS and OS-pPET-RadScore, Barcelona-Clinic Liver Cancer staging system and serum alpha-fetoprotein level was analyzed to predict PFS and OS in multivariate analysis.
|
29435123 |
2018 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ultrasensitive Detection of Serum MicroRNA Using Branched DNA-Based SERS Platform Combining Simultaneous Detection of α-Fetoprotein for Early Diagnosis of Liver Cancer.
|
30238748 |
2018 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The 20-week survival rate of DEN-induced liver cancer rats administered with oral 1,4-GL was increased from 45.0 to 70.0% with reduced carcinogenesis of the liver and significantly lowered serum α-fetoprotein level (14.28 ± 2.89 ng/mL vs. 18.56 ± 4.65 ng/mL, p = 0.012).
|
31070541 |
2018 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, analyzing data from The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA-LIHC) and GSE14520 datasets revealed a significant correlation between MED15 expression and the tumor size (P=0.033), Barcelona Clinic Liver Cancer stage (P=0.031), α-fetoprotein levels (P=0.002) and metastasis risk (P=0.001).
|
29556287 |
2018 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conductometric immunoassay of alpha-fetoprotein in sera of liver cancer patients using bienzyme-functionalized nanometer-sized silica beads.
|
30398232 |
2018 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Conversely, higher Child-Pugh class, alpha-fetoprotein levels over 400 kU/L, and later BCLC disease stages were each associated with higher mortality.
|
30309301 |
2018 |
Malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The prognostic systems Okuda, The Cancer of the Liver Italian Program (CLIP), the Chinese University Prognostic Index (CUPI), Groupe d'Etude et de Traitément du Carcinome Hepatocellulaire (GRETCH), the modified TNM-based Japan Integrated Score (JIS) combined with alpha-fetoprotein and Child-Turcotte-Pugh (CTP), the TNM system, and the Barcelona Clinic Liver Cancer Classification (BCLC) were applied to these patients and compared through model fit measurements, likelihood scores, and the Akaike Information Criterion (AIC).
|
29617435 |
2018 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alpha fetoprotein assessment by using a nano optical sensor thin film binuclear Pt-2-aminobenzimidazole-Bipyridine for early diagnosis of liver cancer.
|
29784373 |
2018 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the immunogenicity of AFP is weak and it could induce the immune escapes through inhibiting the function of dendritic cells, natural killer cells, and T lymphocytes, AFP has attracted more attention in liver cancer immunotherapy.
|
29805966 |
2018 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HBx drives alpha fetoprotein expression to promote initiation of liver cancer stem cells through activating PI3K/AKT signal pathway.
|
27925189 |
2017 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the study, liver cancer biomarker alpha-fetoprotein (AFP) was used as an assay model, two different antibodies were labeled with SNPs and fluorophore Alexa Fluor 488, respectively.
|
28436659 |
2017 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
AFP is an important target in the treatment of liver cancer.
|
28554567 |
2017 |